- Home
- CXE vs AGEN Comparison
CXE vs AGEN Comparison
Compare CXE & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CXE | AGEN |
|---|---|---|
| Founded | 1989 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.9M | 126.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CXE | AGEN |
|---|---|---|
| Price | $3.88 | $3.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 62.9K | ★ 613.6K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $106,829,000.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | N/A | $68.25 |
| P/E Ratio | $51.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.95 | $1.38 |
| 52 Week High | $3.67 | $7.34 |
Technical Indicators
Market Signals| Indicator | CXE | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 72.96 | 45.17 |
| Support Level | $3.75 | $2.76 |
| Resistance Level | $3.84 | $3.15 |
| Average True Range (ATR) | 0.03 | 0.18 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 90.00 | 61.00 |
Price Performance
Historical ComparisonAbout CXE MFS High Income Municipal Trust
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).